Oppenheimer Maintains Outperform Rating for Soleno Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Oppenheimer has maintained its Outperform rating for Soleno Therapeutics (NASDAQ:SLNO) and increased its price target from $8.00 to $14.00. Soleno Therapeutics' shares are currently trading up 8.37% over the last 24 hours, at $4.59 per share. A move to $14.00 would account for a 204.68% increase from the current share price.
September 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained its Outperform rating for Soleno Therapeutics and raised its price target, indicating a positive outlook for the company. The stock is currently trading up 8.37%.
The maintained Outperform rating and increased price target by Oppenheimer indicates a positive outlook for Soleno Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100